FDA approves Pebrilzo, but settlement delays Biocon’s U.S. launch
FDA approved Biocon’s Pebrilzo for HER2-positive breast cancer, with no clinically meaningful differences from Perjeta. A Genentech settlement defers U.S. launch until at least Q3 2028.
TAG E-2578 · 553 words on the filing

Summary of findings
- Biocon announced FDA approval of Pebrilzo (pertuzumab-qcay) for HER2-positive breast cancer on November 16, 2026.
- FDA found no clinically meaningful differences from Perjeta in quality, safety, efficacy, or immunogenicity.
- A global settlement with Genentech delays the U.S. launch until at least Q3 2028.
- Pebrilzo is Biocon’s fifth oncology biosimilar to receive U.S. FDA approval.
- Biocon expects about 320,000 U.S. breast cancer diagnoses in 2026, with approximately 20% HER2-positive.
Biocon’s Pebrilzo won FDA approval as a pertuzumab biosimilar, but a global settlement with Genentech blocks its U.S. launch until at least the third quarter of 2028. Regulatory clearance therefore arrives well before commercial entry.
Biocon announced the decision on November 16, 2026. Pebrilzo, spelled pertuzumab-qcay, is a biosimilar to Genentech’s Perjeta (pertuzumab), the reference product. It is a monoclonal antibody for HER2-positive breast cancer. The drug blocks HER2 receptors on cancer cells.
What did FDA approve?
FDA approved Pebrilzo for HER2-positive breast cancer. The agency found no clinically meaningful differences between Pebrilzo and Perjeta in quality, safety, efficacy, or immunogenicity. Those four measures cover the main dimensions of the biosimilar comparison.
The finding establishes regulatory approval, not immediate U.S. availability. The stated commercial floor remains the third quarter of 2028 under the global settlement with Genentech. Approval and launch are separate milestones.
Takeaway: Pebrilzo has U.S. regulatory clearance, but the settlement still controls when Biocon can enter the market.
What has Europe decided?
The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended granting marketing authorization for Pebrilzo in September. The positive opinion covered HER2-positive breast cancer across multiple disease stages.
That was a CHMP recommendation, not final European marketing authorization. The announcement did not specify a European commercial launch timetable. The European process remains separate from the Genentech settlement governing U.S. entry.
Takeaway: Europe has a positive CHMP opinion, while U.S. commercialization remains tied to the 2028 settlement.
How does Pebrilzo fit Biocon’s portfolio?
Biocon’s existing U.S. biosimilar portfolio already included four products named in the announcement:
- Ogivri (trastuzumab-dkst)
- Jobevne (bevacizumab-nwgd)
- Fulphila (pegfilgrastim-jmdb)
- Aukelso (denosumab-kyqq)
Biocon also has proposed biosimilars for:
- Trastuzumab/hyaluronidase
- Nivolumab
- Pembrolizumab
Pebrilzo adds a fifth oncology biosimilar approval to the company’s U.S. record. It does not yet permit a U.S. pertuzumab launch.
Shreehas Tambe, chief executive and managing director, said: “For patients diagnosed with HER2-positive breast cancer, the burden of the disease extends well beyond the physical challenges. [This places] considerable financial strain on patients and their families.” He added: “As our fifth oncology biosimilar to receive U.S. FDA approval, PEBRILZO strengthens our anti-cancer portfolio and advances our commitment.”
Takeaway: Biocon adds an approved HER2 antibody to its U.S. regulatory portfolio, while three named biosimilars remain proposed pipeline assets.
How large is the expected patient pool?
Biocon estimates that approximately 320,000 U.S. women will be diagnosed with breast cancer by the end of 2026. About 20% of those expected diagnoses will be HER2-positive, or roughly one in five. The company also says one in eight women will be diagnosed with breast cancer during their lifetime.
Biocon presents the HER2-positive share as evidence of a continuing need for additional treatment options. The approval meets that stated need at the regulatory level, but the settlement delays Biocon’s ability to supply the U.S. market with Pebrilzo.
The separation between approval and launch is the defining commercial constraint. Biocon cannot translate U.S. clearance into product sales before at least the third quarter of 2028.
Takeaway: The expected patient need is substantial, but Biocon cannot convert U.S. approval into Pebrilzo sales before the settlement window opens.
via FDA industry wire (Google News) (Source)
More from Grace Kim
Show full bio
Market editor covering companies, deals and strategy in global pharmaceutical industry at PharmInsider.
7 articles
Linked filings
- C-4460
- K-4971
- P-6323
- K-2547
- K-7275